The ability of HMGA2 in cancer (stem) cells to affect the stability of interphase telomeres and increase the resistance to telomere-targeting drugs identifies HMGA2 as an attractive novel therapeutic target to induce lethal telomere-mediated genomic instability in HMGA2+ cancer cells. This evidence concerns the gene HMGA2 and cancer.